This article is more than 5 years old. Information may no longer be current.
iStent inject approval tops recent glaucoma news
Glaucoma news in recent months as reported on Healio.com/OSN has included FDA approvals, study results and video perspectives from meetings.
Here are some of the latest most-read articles and most-watched videos:
FDA approves iStent inject
The iStent inject trabecular micro-bypass system has received premarket approval from the FDA for the reduction of IOP. Read more.
Bimatoprost sustained-release implant shows positive phase 3 data
A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a phase 3 clinical study. Read more.
VIDEO: Rhopressa works as primary agent in certain glaucoma conditions
At the Kiawah Eye meeting, Savak Teymoorian, MD, MBA, discusses certain situations in which Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) can serve as a primary agent in the treatment of glaucoma. Watch here.
VIDEO: Presbyopia-correcting treatments, MIGS entering new phase of innovation
Elizabeth Yeu, MD, discusses a panel she moderated on presbyopia-correcting technologies and MIGS devices for the treatment of glaucoma at OCTANe’s Ophthalmology Technology Summit. Watch here.
VIDEO: Aerie continues push in glaucoma, retina products
Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, delivers an update on the company’s progress in bringing new glaucoma and retina treatment therapeutics into the U.S. market. Watch here.